Keywords: AE; adverse event; AML; acute myeloid leukemia; APC; anaphase promoting complex; CLL; chronic lymphocytic leukemia; CPC; chromosomal passenger complex; CR; complete response; CRi; complete remission with incomplete blood count recovery; FDA; Food and Drug